FDA Grants Approval for Propofol ANDA220857 by Anthea Pharma
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) 220857 for Propofol submitted by Anthea Pharma.
Company
Anthea Pharma
Asset
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of Anthea Pharma's generic Propofol represents a significant shift in the anesthesia market, introducing increased competition that could impact pricing strategies. Pharma strategy teams should closely monitor market dynamics and competitor responses to assess potential impacts on revenue and market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market uptake of Anthea Pharma's Propofol and any responses from existing manufacturers.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.